Novavax, Inc. (NASDAQ:NVAX) Receives $17.83 Average PT from Analysts

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has received a consensus rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $17.83.

A number of equities research analysts recently commented on the company. B. Riley reaffirmed a "buy" rating and set a $26.00 price objective (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. Jefferies Financial Group decreased their price objective on shares of Novavax from $31.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, October 16th. Finally, HC Wainwright reiterated a "buy" rating and issued a $19.00 target price on shares of Novavax in a report on Tuesday, December 10th.

Novavax Stock Performance

Shares of NVAX opened at $8.40 on Friday. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -3.72 and a beta of 2.07. Novavax has a 52 week low of $3.53 and a 52 week high of $23.86. The business's fifty day moving average price is $8.62 and its two-hundred day moving average price is $10.99.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. The firm's revenue for the quarter was down 54.8% compared to the same quarter last year. During the same period last year, the business posted ($1.26) EPS. As a group, research analysts forecast that Novavax will post -1.31 EPS for the current year.

Insider Buying and Selling at Novavax

In other news, Director James F. Young sold 5,400 shares of the firm's stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the transaction, the director now directly owns 51,760 shares of the company's stock, valued at $414,080. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Rachel K. King sold 4,150 shares of the business's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the sale, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. This represents a 21.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,150 shares of company stock valued at $119,641 in the last 90 days. 1.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Novavax

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVAX. Amalgamated Bank increased its position in shares of Novavax by 26.9% in the second quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company's stock valued at $62,000 after acquiring an additional 1,036 shares during the last quarter. Ensign Peak Advisors Inc boosted its holdings in shares of Novavax by 3.0% in the 2nd quarter. Ensign Peak Advisors Inc now owns 44,900 shares of the biopharmaceutical company's stock valued at $568,000 after buying an additional 1,300 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 1,598 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Novavax by 12.0% in the third quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company's stock valued at $244,000 after acquiring an additional 2,072 shares during the last quarter. Finally, Creative Planning grew its position in shares of Novavax by 12.5% in the 2nd quarter. Creative Planning now owns 24,143 shares of the biopharmaceutical company's stock valued at $306,000 after acquiring an additional 2,692 shares during the period. 53.04% of the stock is owned by institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.